IN2015DN02349A - - Google Patents

Download PDF

Info

Publication number
IN2015DN02349A
IN2015DN02349A IN2349DEN2015A IN2015DN02349A IN 2015DN02349 A IN2015DN02349 A IN 2015DN02349A IN 2349DEN2015 A IN2349DEN2015 A IN 2349DEN2015A IN 2015DN02349 A IN2015DN02349 A IN 2015DN02349A
Authority
IN
India
Prior art keywords
conjugates
specific
peptide
binding protein
drug
Prior art date
Application number
Other languages
English (en)
Inventor
Limited Polytherics
Original Assignee
Polytherics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2013/051593 external-priority patent/WO2013190292A2/fr
Application filed by Polytherics Ltd filed Critical Polytherics Ltd
Publication of IN2015DN02349A publication Critical patent/IN2015DN02349A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN2349DEN2015 2012-10-24 2013-10-11 IN2015DN02349A (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261717743P 2012-10-24 2012-10-24
US201261717710P 2012-10-24 2012-10-24
US201361811285P 2013-04-12 2013-04-12
PCT/GB2013/051593 WO2013190292A2 (fr) 2012-06-19 2013-06-19 Nouveau procédé de préparation de conjugués d'anticorps et nouveaux conjugués d'anticorps
PCT/GB2013/052661 WO2014064423A1 (fr) 2012-10-24 2013-10-11 Conjugués médicament-protéine

Publications (1)

Publication Number Publication Date
IN2015DN02349A true IN2015DN02349A (fr) 2015-08-28

Family

ID=50544085

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2349DEN2015 IN2015DN02349A (fr) 2012-10-24 2013-10-11

Country Status (19)

Country Link
US (2) US20150290342A1 (fr)
EP (2) EP2911700B1 (fr)
JP (1) JP6328648B2 (fr)
KR (1) KR102209395B1 (fr)
CN (1) CN104870021B (fr)
AU (1) AU2013336409B2 (fr)
BR (1) BR112015008376A2 (fr)
CA (1) CA2884299A1 (fr)
DK (1) DK2911700T5 (fr)
ES (1) ES2623209T3 (fr)
HK (1) HK1208187A1 (fr)
IL (1) IL237672B (fr)
IN (1) IN2015DN02349A (fr)
MX (1) MX2015005122A (fr)
MY (1) MY169147A (fr)
RU (1) RU2015119561A (fr)
SG (1) SG11201501618WA (fr)
WO (1) WO2014064423A1 (fr)
ZA (1) ZA201501642B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2913732A1 (fr) * 2013-06-04 2014-12-11 Cytomx Therapeutics, Inc. Compositions et procedes permettant de conjuguer des anticorps activables
PT3057585T (pt) 2013-10-15 2020-10-21 Seagen Inc Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando
WO2015179734A1 (fr) * 2014-05-23 2015-11-26 Novartis Ag Procédés pour la fabrication ce conjugués à partir de protéines contenant des liaisons disulfures
KR102451080B1 (ko) * 2014-06-12 2022-10-06 씨에스피씨 메가리스 바이오파마슈티칼 씨오., 엘티디. 효소적 방법을 통한 균일한 항체 약물 접합체
EP3218009B1 (fr) 2014-10-14 2021-04-07 Polytherics Limited Procédé pour la conjugaison d'un peptide ou d'une protéine avec un réactif comprenant un groupe partant comportant une partie de peg
WO2016063006A1 (fr) * 2014-10-24 2016-04-28 Polytherics Limited Conjugués et réactifs de conjugaison
GB201419108D0 (en) 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
TWI660741B (zh) 2015-11-03 2019-06-01 財團法人工業技術研究院 抗體藥物複合物及其製造方法
MX2018006218A (es) 2015-12-04 2018-09-05 Seattle Genetics Inc Conjugados de compuestos de tubulisina cuaternizada.
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
WO2017161206A1 (fr) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugués contenant des anticorps à activité conditionnelle ou des fragments de liaison à un antigène associés, et procédés d'utilisation
BR112018069273A2 (pt) 2016-03-25 2019-01-22 Seattle Genetics Inc métodos para preparação de um composto e para tratamento de um indivíduo com uma malignidade hematológica, composto, composição, e, intermediário ligante de fármaco ou composto ligante de fármaco
EP3442595A1 (fr) 2016-04-14 2019-02-20 Polytherics Limited Conjugués et réactifs de conjugaison comprenant un lieur qui comprend au moins deux motifs (-ch2-ch2-o-) dans un cycle
GB201608936D0 (en) 2016-05-20 2016-07-06 Polytherics Ltd Novel conjugates and novel conjugating reagents
CN109311996B (zh) * 2016-06-06 2023-11-28 阿布泽纳(英国)有限公司 抗体、其用途及其缀合物
GB201614162D0 (en) * 2016-08-18 2016-10-05 Polytherics Ltd Antibodies, uses thereof and conjugates thereof
MX2019010769A (es) 2017-03-24 2019-12-11 Seattle Genetics Inc Proceso para la preparacion de enlazadores de farmacos de glucuronidos y compuestos intermediarios de los mismos.
GB201820864D0 (en) * 2018-12-20 2019-02-06 J A Kemp Antibody-drug conjugates
KR20230002672A (ko) * 2020-04-15 2023-01-05 선전 엔듀어링 바이오테크 리미티드 항체-약물 접합체
AU2022237459A1 (en) * 2021-03-19 2023-09-21 Shenzhen Enduring Biotech, Ltd. Pegylated t cell engager with dual specificities to cd3 and cd19
WO2023141855A1 (fr) * 2022-01-27 2023-08-03 Glyco-Therapy Biotechnology Co., Ltd. Conjugués protéiques à charges utiles multiples et leurs procédés de fabrication

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
DK1725249T3 (en) 2003-11-06 2014-03-17 Seattle Genetics Inc Monomethylvaline compounds capable of conjugating to ligands.
EA016577B1 (ru) * 2005-09-26 2012-06-29 Медарекс, Инк. Конъюгаты антитело-лекарство и их применение
PT2211904T (pt) * 2007-10-19 2016-11-02 Seattle Genetics Inc Agentes de ligação a cd19 e seus usos
ES2647927T3 (es) 2008-03-18 2017-12-27 Seattle Genetics, Inc. Conjugados enlazadores del fármaco auriestatina
BRPI0911442A2 (pt) * 2008-04-30 2019-03-12 Immunogen, Inc. conjugados potentes e ligantes hidrofílicos
EP2403538B1 (fr) 2009-03-04 2017-10-04 Polytherics Limited Protéines et peptides conjugués
WO2010120561A1 (fr) * 2009-04-01 2010-10-21 Genentech, Inc. Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
UY32913A (es) * 2009-10-02 2011-04-29 Sanofi Aventis Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuero
EP2841958A1 (fr) * 2012-04-25 2015-03-04 Koninklijke Philips N.V. Système et procédé de localisation d'une bobine de gradient
KR20150023027A (ko) * 2012-06-19 2015-03-04 폴리테릭스 리미티드 항체 접합체의 제조를 위한 신규한 공정 및 신규한 항체 접합체

Also Published As

Publication number Publication date
AU2013336409B2 (en) 2017-08-03
KR102209395B1 (ko) 2021-01-28
DK2911700T3 (en) 2017-05-15
SG11201501618WA (en) 2015-04-29
BR112015008376A2 (pt) 2017-09-26
HK1208187A1 (en) 2016-02-26
JP6328648B2 (ja) 2018-05-23
RU2015119561A (ru) 2016-12-20
AU2013336409A1 (en) 2015-04-02
EP3159013A1 (fr) 2017-04-26
KR20150103656A (ko) 2015-09-11
IL237672A0 (en) 2015-04-30
ES2623209T3 (es) 2017-07-10
WO2014064423A1 (fr) 2014-05-01
IL237672B (en) 2018-02-28
MY169147A (en) 2019-02-18
CN104870021A (zh) 2015-08-26
JP2015533847A (ja) 2015-11-26
MX2015005122A (es) 2015-10-29
EP2911700B1 (fr) 2017-02-08
US20150290342A1 (en) 2015-10-15
ZA201501642B (en) 2016-01-27
US20220062436A1 (en) 2022-03-03
CN104870021B (zh) 2018-03-13
EP2911700A1 (fr) 2015-09-02
CA2884299A1 (fr) 2014-05-01
DK2911700T5 (en) 2017-05-22

Similar Documents

Publication Publication Date Title
IN2015DN02349A (fr)
CY1122490T1 (el) Αντισωματα κατα του ανθρωπινου cd38
MX2015005124A (es) Conjugados de farmaco-proteina.
MY168297A (en) Cytotoxic Peptides and Antibody Drug Conjugates Thereof
PH12015500390B1 (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
EA201691023A1 (ru) Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
TN2013000245A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib
TN2015000396A1 (en) Antibody drug conjugates
NZ703581A (en) Anti-cd70 antibody drug conjugates
NZ630542A (en) Methods of treating a tauopathy
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
UA113712C2 (xx) Антитіло до fap і способи його застосування
TN2011000232A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 melphalan
MX340062B (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y ciclofosfamida.
PH12018500159A1 (en) Constructs targeting psa peptide/mhc complexes and uses thereof
MX2013002718A (es) Composiciones de anticuerpo anti-vegfr-3.
MX2013003168A (es) Anticuerpo contra ephrin b2 y su uso.
TN2013000068A1 (en) Anti-vegfr-3 antibody compositions
TN2011000153A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide